Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Aclaris_Therapeutics
|
| gptkbp:activities |
inhibits viral replication
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:Atea_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
ATI-501
|
| gptkbp:indication |
treatment of COVID-19
|
| gptkbp:manager |
oral
|
| gptkbp:social_structure |
nucleotide analog
|
| gptkbp:status |
investigational
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
oral antiviral
|